Kerrisdale Capital Issues Negative Report on Prothena Corporation PLC and Announces Conference Call Schedule

Wednesday, November 8, 2017 Corporate News
Email Print This Page Comment bookmark
Font : A-A+

- Kerrisdale believes that Prothena's lead drug NEOD001 will fail in its current Phase 2b and Phase 3 trials

NEW YORK, Nov. 8, 2017 /PRNewswire/ -- Kerrisdale Capital, a private investment manager, has published a negative report

explaining its short position in Prothena Corporation PLC (PRTA), a $2.4 billion development-stage biotechnology company whose valuation is primarily based on lead drug candidate NEOD001, an antibody currently in trials to treat AL amyloidosis. Prothena's stock price has increased over 700% since its spin-off from Elan in 2012 despite no evidence that its principal asset NEOD001 works. Kerrisdale believes that NEOD001 is a poorly-understood drug that will fail its Phase 2b and Phase 3 trials.

The full report can be found at http://kerr.co/prta.

Kerrisdale has a short position in Prothena Corporation PLC and stands to benefit if its share price falls.

Conference Call ScheduleKerrisdale will host a conference call on Wednesday, November 8 at 10:30am ET to discuss the Prothena report.

To participate in the conference call, dial 888-567-1602 (US and Canada) or 404-267-0373 (international) and reference the Kerrisdale Capital call.

About Kerrisdale CapitalKerrisdale Capital Management, LLC, is a fundamentally-oriented investment manager that focuses on long-term value investments and event-driven special situations.

ContactAgnes CaoKerrisdale Capital  [email protected]  212-257-4385

Kerrisdale Capital Management, LLC is a member of the Financial Industry Regulatory Authority, CRD number 160804.

View original content:http://www.prnewswire.com/news-releases/kerrisdale-capital-issues-negative-report-on-prothena-corporation-plc-and-announces-conference-call-schedule-300551842.html

SOURCE Kerrisdale Capital Management, LLC



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store